These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22990663)

  • 1. Molecular dynamics and free energy studies on Aurora kinase A and its mutant bound with MLN8054: insight into molecular mechanism of subtype selectivity.
    Yang Y; Shen Y; Li S; Jin N; Liu H; Yao X
    Mol Biosyst; 2012 Nov; 8(11):3049-60. PubMed ID: 22990663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design.
    Dodson CA; Kosmopoulou M; Richards MW; Atrash B; Bavetsias V; Blagg J; Bayliss R
    Biochem J; 2010 Mar; 427(1):19-28. PubMed ID: 20067443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.
    Manfredi MG; Ecsedy JA; Meetze KA; Balani SK; Burenkova O; Chen W; Galvin KM; Hoar KM; Huck JJ; LeRoy PJ; Ray ET; Sells TB; Stringer B; Stroud SG; Vos TJ; Weatherhead GS; Wysong DR; Zhang M; Bolen JB; Claiborne CF
    Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4106-11. PubMed ID: 17360485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo.
    Huck JJ; Zhang M; McDonald A; Bowman D; Hoar KM; Stringer B; Ecsedy J; Manfredi MG; Hyer ML
    Mol Cancer Res; 2010 Mar; 8(3):373-84. PubMed ID: 20197380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular docking/dynamics studies of Aurora A kinase inhibitors.
    Talele TT; McLaughlin ML
    J Mol Graph Model; 2008 Jun; 26(8):1213-22. PubMed ID: 18096419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis of specific binding between Aurora A and TPX2 by molecular dynamics simulations.
    Cheng Y; Zhang F; Chen Q; Gao J; Cui W; Ji M; Tung CH
    J Chem Inf Model; 2011 Oct; 51(10):2626-35. PubMed ID: 21919471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of Aurora B activation by INCENP and inhibition by hesperadin.
    Sessa F; Mapelli M; Ciferri C; Tarricone C; Areces LB; Schneider TR; Stukenberg PT; Musacchio A
    Mol Cell; 2005 Apr; 18(3):379-91. PubMed ID: 15866179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-resistant aurora A mutants for cellular target validation of the small molecule kinase inhibitors MLN8054 and MLN8237.
    Sloane DA; Trikic MZ; Chu ML; Lamers MB; Mason CS; Mueller I; Savory WJ; Williams DH; Eyers PA
    ACS Chem Biol; 2010 Jun; 5(6):563-76. PubMed ID: 20426425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.
    Chakravarty A; Shinde V; Tabernero J; Cervantes A; Cohen RB; Dees EC; Burris H; Infante JR; Macarulla T; Elez E; Andreu J; Rodriguez-Braun E; Rosello S; von Mehren M; Meropol NJ; Langer CJ; ONeil B; Bowman D; Zhang M; Danaee H; Faron-Yowe L; Gray G; Liu H; Pappas J; Silverman L; Simpson C; Stringer B; Tirrell S; Veiby OP; Venkatakrishnan K; Galvin K; Manfredi M; Ecsedy JA
    Cancer Res; 2011 Feb; 71(3):675-85. PubMed ID: 21148750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of selective aminothiazole aurora kinase inhibitors.
    Andersen CB; Wan Y; Chang JW; Riggs B; Lee C; Liu Y; Sessa F; Villa F; Kwiatkowski N; Suzuki M; Nallan L; Heald R; Musacchio A; Gray NS
    ACS Chem Biol; 2008 Mar; 3(3):180-92. PubMed ID: 18307303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylation, Mg-ADP, and Inhibitors Differentially Shape the Conformational Dynamics of the A-Loop of Aurora-A.
    Musavizadeh Z; Grottesi A; Guarguaglini G; Paiardini A
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B.
    Aliagas-Martin I; Burdick D; Corson L; Dotson J; Drummond J; Fields C; Huang OW; Hunsaker T; Kleinheinz T; Krueger E; Liang J; Moffat J; Phillips G; Pulk R; Rawson TE; Ultsch M; Walker L; Wiesmann C; Zhang B; Zhu BY; Cochran AG
    J Med Chem; 2009 May; 52(10):3300-7. PubMed ID: 19402633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy.
    Hoar K; Chakravarty A; Rabino C; Wysong D; Bowman D; Roy N; Ecsedy JA
    Mol Cell Biol; 2007 Jun; 27(12):4513-25. PubMed ID: 17438137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity.
    LeRoy PJ; Hunter JJ; Hoar KM; Burke KE; Shinde V; Ruan J; Bowman D; Galvin K; Ecsedy JA
    Cancer Res; 2007 Jun; 67(11):5362-70. PubMed ID: 17545617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: safety, pharmacokinetics, and pharmacodynamics.
    Macarulla T; Cervantes A; Elez E; Rodríguez-Braun E; Baselga J; Roselló S; Sala G; Blasco I; Danaee H; Lee Y; Ecsedy J; Shinde V; Chakravarty A; Bowman D; Liu H; Eton O; Fingert H; Tabernero J
    Mol Cancer Ther; 2010 Oct; 9(10):2844-52. PubMed ID: 20724522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MLN8054, a small molecule inhibitor of aurora kinase a, sensitizes androgen-resistant prostate cancer to radiation.
    Moretti L; Niermann K; Schleicher S; Giacalone NJ; Varki V; Kim KW; Kopsombut P; Jung DK; Lu B
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1189-97. PubMed ID: 21514073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aurora A and B kinases as targets for cancer: will they be selective for tumors?
    Matthews N; Visintin C; Hartzoulakis B; Jarvis A; Selwood DL
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):109-20. PubMed ID: 16375648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
    Bhunia SS; Roy KK; Saxena AK
    J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some insights into the binding mechanism of Aurora B kinase gained by molecular dynamics simulation.
    Xiong R; Cai XM; Wei J; Ren PY
    J Mol Model; 2012 Oct; 18(10):4591-601. PubMed ID: 22643974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
    Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
    Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.